A recent Tax Appeal Commission case gives an insight into the flow of monies surrounding the supply of a particular drug, and the Vat treatment of the supply of drugs in general.  The Appellant in the tax case is a drug company. While the drug is not named, it is described as an innovative treatment requiring ongoing use i.e. not a one-off cure.  The first link in the financial chain is the sale of the drug, by the drug company, to an authorised wholesaler at a defined “ex-factory price”, calculated as the maximum of an average sales price in a…

Read on for just €1

For a limited time, get your first month for €1 and unlock full access to The Currency and The Wall Street Journal – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .